Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Systematic review

Vol. 154 No. 7 (2024)

Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis

DOI
https://doi.org/10.57187/s.3695
Cite this as:
Swiss Med Wkly. 2024;154:3695
Published
25.07.2024

Summary

AIM: This study aims to evaluate the prognostic role of the KRAS G12C mutation in patients with advanced non-small cell lung cancer and PD-L1 expression ≥50% who are treated with immune checkpoint inhibitor monotherapy.

METHODS: We conducted a systematic review of clinical studies fulfilling the following criteria: (1) enrolling patients with advanced/metastatic non-small cell lung cancer with high PD-L1 tumour expression receiving first-line therapy with anti-PD-(L)1 immune checkpoint inhibitors; (2) comparing the outcomes of patients with the KRAS G12C mutation to those without this mutation, and (3) reporting overall survival and progression-free survival (PFS). The electronic databases Medline, EMBASE, Cochrane and Google Scholar, along with reference lists, were systematically searched.

RESULTS: We identified four publications that fulfilled the inclusion criteria, comprising a total of 469 patients. Of these, two studies reported hazard ratios (HR) for PFS, resulting in a final pooled patient sample of 163 for the meta-analysis. In patients with non-small cell lung cancer who received anti-PD-(L)1 monotherapy, the presence of a KRAS G12C mutation was associated with improved PFS compared to patients with KRAS wild-type tumours, with a pooled hazard ratio of 0.39 and a 95% Confidence Interval (CI) of 0.25–0.63. Among all patients with KRAS mutations, those harbouring a KRAS G12C mutation had improved PFS compared to patients with any other KRAS mutation (pooled HR 0.33, 95% CI 0.19–0.57).

CONCLUSIONS: Patients with non-small cell lung cancer who have the KRAS G12C mutation and high PD-L1 expression demonstrate favourable PFS with first-line PD-(L)1 immune checkpoint inhibitor monotherapy compared to patients with KRASwt or other KRAS mutations and high PD-L1 expression.

References

  1. WHO: Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=lung%20(1.80%20million%20deaths)%3B,rectum%20(916%20000%20deaths)%3B
  2. Elkrief A, Joubert P, Florescu M, Tehfe M, Blais N, Routy B. Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020 [Erratum in: Curr Oncol. 2020 Jun;27] [3] [:e349. PMID: 32218661; PMCID: PMC7096203]. Curr Oncol. 2020 Feb;27(1):52–60. 10.3747/co.27.5953
  3. Annals of Oncology 29 (Supplement 4): iv192–iv237, 2018. doi:10.1093/annonc/mdy275, Published online 3 October 2018; updated 26 January 2019
  4. National Comprehensive Cancer Network. Non-Small cell lung cancer (Version 3.2022). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed July 27, 2022.
  5. Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2021 Mar;39(9):1040–91. 10.1200/JCO.20.03570 DOI: https://doi.org/10.1200/JCO.20.03570
  6. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019 Mar;37(7):537–46. 10.1200/JCO.18.00149 DOI: https://doi.org/10.1200/JCO.18.00149
  7. Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021 Jul;32(7):881–95. 10.1016/j.annonc.2021.04.008 DOI: https://doi.org/10.1016/j.annonc.2021.04.008
  8. Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. 2020 Oct;15(10):1657–69. 10.1016/j.jtho.2020.06.015 DOI: https://doi.org/10.1016/j.jtho.2020.06.015
  9. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al.; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [Erratum in: Ann Oncol. 2019 May;30] [5] [:863-870. PMID: 30285222]. Ann Oncol. 2018 Oct;29 Suppl 4:iv192–237. 10.1093/annonc/mdy275 DOI: https://doi.org/10.1093/annonc/mdy275
  10. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 May;20(5):497–530. 10.6004/jnccn.2022.0025
  11. Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, et al. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer. 2019 Jun;132:65–71. 10.1016/j.lungcan.2019.04.005 DOI: https://doi.org/10.1016/j.lungcan.2019.04.005
  12. Dong ZY, Zhang JT, Liu SY, Su J, Zhang C, Xie Z, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. OncoImmunology. 2017 Jul;6(11):e1356145. 10.1080/2162402X.2017.1356145 DOI: https://doi.org/10.1080/2162402X.2017.1356145
  13. Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. Int J Mol Sci. 2021 Jun;22(12):6288. 10.3390/ijms22126288 DOI: https://doi.org/10.3390/ijms22126288
  14. Tao L, Miao R, Mekhail T, Sun J, Meng L, Fang C, et al. The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma. Clin Lung Cancer. 2020; 10.1016/j.cllc.2020.07.00 DOI: https://doi.org/10.1016/j.cllc.2020.07.004
  15. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 Jul;387(2):120–31. 10.1056/NEJMoa2204619 DOI: https://doi.org/10.1056/NEJMoa2204619
  16. ROBINS-E Development Group (Higgins J, Morgan R, Rooney A, Taylor K, Thayer K, Silva R, Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness L, Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J, Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T, Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J). Risk Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). Launch version, 20 June 2023.
  17. Cefalì M, Epistolio S, Ramelli G, Mangan D, Molinari F, Martin V, et al. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. J Clin Med. 2022 Mar;11(6):1627. 10.3390/jcm11061627 DOI: https://doi.org/10.3390/jcm11061627
  18. Frost N, Kollmeier J, Vollbrecht C, Grah C, Matthes B, Pultermann D, et al. KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma. Transl Lung Cancer Res. 2021 Feb;10(2):737–52. 10.21037/tlcr-20-958 DOI: https://doi.org/10.21037/tlcr-20-958
  19. Wu SG, Liao WY, Su KY, Yu SL, Huang YL, Yu CJ, et al. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. JTO Clin Res Rep. 2020 Dec;2(2):100140. 10.1016/j.jtocrr.2020.100140 DOI: https://doi.org/10.1016/j.jtocrr.2020.100140
  20. Kartolo A, Feilotter H, Hopman W, Fung AS, Robinson A. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors. Cancer Treat Res Commun. 2021;27:100330. 10.1016/j.ctarc.2021.100330 DOI: https://doi.org/10.1016/j.ctarc.2021.100330
  21. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 Jul;8(7):822–35. 10.1158/2159-8290.CD-18-0099
  22. Spagnuolo A, Maione P, Gridelli C. The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review. Transl Lung Cancer Res. 2022 Jun;11(6):1199–216. 10.21037/tlcr-21-948 DOI: https://doi.org/10.21037/tlcr-21-948
  23. Tani T, Kitajima S, Conway EB, Knelson EH, Barbie DA. KRAS G12C inhibition and innate immune targeting. Expert Opin Ther Targets. 2021 Mar;25(3):167–74. 10.1080/14728222.2021.1902991 DOI: https://doi.org/10.1080/14728222.2021.1902991
  24. Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021 Sep;32(9):1101–10. 10.1016/j.annonc.2021.06.001 DOI: https://doi.org/10.1016/j.annonc.2021.06.001
  25. Zhang SS, Nagasaka M. Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021 Oct;12:115–22. 10.2147/LCTT.S334623 DOI: https://doi.org/10.2147/LCTT.S334623
  26. Li JX, Li RZ, Ma LR, Wang P, Xu DH, Huang J, et al. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives. Front Pharmacol. 2022 Apr;13:875330. 10.3389/fphar.2022.875330 DOI: https://doi.org/10.3389/fphar.2022.875330
  27. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217–23. 10.1038/s41586-019-1694-1 DOI: https://doi.org/10.1038/s41586-019-1694-1
  28. Chen N, Fang W, Lin Z, Peng P, Wang J, Zhan J, et al. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol Immunother. 2017 Sep;66(9):1175–87. 10.1007/s00262-017-2005-z DOI: https://doi.org/10.1007/s00262-017-2005-z
  29. Liu C, Zheng S, Jin R, Wang X, Wang F, Zang R, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2020 Feb;470:95–105. 10.1016/j.canlet.2019.10.027 DOI: https://doi.org/10.1016/j.canlet.2019.10.027
  30. Torralvo J, Friedlaender A, Achard V, Addeo A. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience. Cancer Genomics Proteomics. 2019;16(6):577–82. 10.21873/cgp.20160 DOI: https://doi.org/10.21873/cgp.20160
  31. Sun L, Hsu M, Cohen RB, Langer CJ, Mamtani R, Aggarwal C. Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JAMA Oncol. 2021 Jun;7(6):937–9. 10.1001/jamaoncol.2021.0546 DOI: https://doi.org/10.1001/jamaoncol.2021.0546
  32. Landre T, Justeau G, Assié JB, Chouahnia K, Davoine C, Taleb C, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022 Mar;71(3):719–26. 10.1007/s00262-021-03031-1 DOI: https://doi.org/10.1007/s00262-021-03031-1
  33. Sciortino C, Viglialoro V, Nucci M, Polito MG, Cortesi E, Gelibter A, et al. Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study. Oncotarget. 2022 May;13(1):686–93. 10.18632/oncotarget.28230 DOI: https://doi.org/10.18632/oncotarget.28230
  34. Sebastian M, Eberhardt WE, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, et al.; CRISP Registry Group. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 2021 Apr;154:51–61. 10.1016/j.lungcan.2021.02.005 DOI: https://doi.org/10.1016/j.lungcan.2021.02.005
  35. Arbour KC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, et al. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Apr;27(8):2209–15. 10.1158/1078-0432.CCR-20-4023 DOI: https://doi.org/10.1158/1078-0432.CCR-20-4023
  36. Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, et al. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2019 Jun;14(6):1095–101. 10.1016/j.jtho.2019.01.011 DOI: https://doi.org/10.1016/j.jtho.2019.01.011
  37. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 Jun;384(25):2371–81. 10.1056/NEJMoa2103695 DOI: https://doi.org/10.1056/NEJMoa2103695
  38. Corral de la Fuente E, Olmedo Garcia ME, Gomez Rueda A, Lage Y, Garrido P. Targeting KRAS in Non-Small Cell Lung Cancer. Front Oncol. 2022 Jan;11:792635. 10.3389/fonc.2021.792635 DOI: https://doi.org/10.3389/fonc.2021.792635
  39. Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017 Jun;23(12):3012–24. 10.1158/1078-0432.CCR-16-2554 DOI: https://doi.org/10.1158/1078-0432.CCR-16-2554
  40. Rosell R, Codony-Servat J, González J, Santarpia M, Jain A, Shivamallu C, et al. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol. 2024 Mar;195:104228. 10.1016/j.critrevonc.2023.104228 DOI: https://doi.org/10.1016/j.critrevonc.2023.104228
  41. Illini O, Fabikan H, Hochmair MJ, Weinlinger C, Krenbek D, Brcic L, et al. Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study. J Clin Med. 2022 Jul;11(14):4098. 10.3390/jcm11144098 DOI: https://doi.org/10.3390/jcm11144098
  42. Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023 Jul;619(7968):160–6. 10.1038/s41586-023-06123-3 DOI: https://doi.org/10.1038/s41586-023-06123-3

Most read articles by the same author(s)